CHAPTER 126-X USE OF CANNABIS FOR THERAPEUTIC PURPOSES
Section 126-X:12
126-X:12 Therapeutic Cannabis Medical Oversight Board Established; Membership; Duties. –
I. There is hereby established the therapeutic cannabis medical oversight board which shall monitor and contribute to the oversight of the clinical, quality, and public health related matters of the use of cannabis for therapeutic purposes under this chapter.
II. The board shall consist of the medical director, department of health and human services, or designee, a qualifying patient, appointed by the commissioner of the department, a clinical representative from an alternative treatment center, appointed by the commissioner, and 10 medical providers also appointed by the commissioner. The medical provider members shall represent the following fields:
(a) Neurology.
(b) Pain management.
(c) Oncology.
(d) Psychiatry.
(e) Pediatrics.
(f) Family or internal medicine.
(g) Obstetrics and gynecology.
(h) Addiction.
(i) Palliative care.
(j) Physiatry/orthopedics.
III. At its first meeting the board shall elect by majority vote a chairperson and an alternate. A quorum shall consist of a majority of members.
IV. The board shall convene at least 2 times per year to monitor and contribute to the oversight of the clinical, quality, and public health related matters of therapeutic cannabis under this chapter by:
(a) Reviewing medical and scientific evidence pertaining to currently approved and additional qualifying conditions.
(b) Reviewing laboratory results of required testing of cannabis cultivated and/or processed by an alternative treatment center and the use of pesticides on products under RSA 126-X:6, III(a)(16).
(c) Monitoring clinical outcomes.
(d) Reviewing training protocols for dispensary staff based on models from other states.
(e) Receiving updates from alternative treatment centers on effectiveness of various strains, types of cannabinoids, and different routes of administration for specific conditions.
(f) Reviewing best practices for medical providers regarding provider education, certification of patients, and patient access to the program.
(g) Reviewing any other clinical, quality, and public health related matter relative to use of cannabis under this chapter.
(h) Developing, reviewing, and updating cannabis product labels and educational material about the risks of cannabis use to be provided to qualifying patients by alternative treatment centers and certifying medical providers.
V. The board may make recommendations to the commissioner to add or remove qualifying medical conditions under RSA 126-X:1, IX based on the findings pursuant to subparagraph IV(a) and after receiving input from the public through a public hearing process. The commissioner may recommend legislation based on the board's findings.
VI. On or before January 1 of each year, the board shall make a report to the president of the senate, the speaker of the house of representatives, the oversight committee on health and human services established under RSA 126-A:13, the board of medicine, and the board of nursing.
Source. 2018, 228:2, eff. Aug. 7, 2018. 2021, 52:1, eff. July 24, 2021. 2023, 237:5, eff. Oct. 7, 2023.